Literature DB >> 10646088

Vaccination against the major infectious diseases.

S A Plotkin1.   

Abstract

The reputation of vaccination rests on a 200-year-old history of success against major infectious diseases. That success has led to the doctrine of 'for each disease, a vaccine'. Although some diseases have proved frustrating, this doctrine carries considerable truth. However, when one reviews the vaccines now available it is apparent that most successes have been obtained when the microbe has a bacteremic or viremic phase during which it is susceptible to the action of neutralizing antibodies, and before replication in the particular organ to which it is tropic. Poliomyelitis and infections by capsulated bacteria are examples where vaccination has worked efficiently. However, some success has also been achieved against agents replicating on respiratory or gastrointestinal mucosae. Influenza, pertussis and rotavirus vaccines are examples of such agents, against which it has been possible to induce immune responses acting locally as well as systemically. In addition, when bacteria produce disease through exotoxins, purification and chemical or genetic inactivation of those toxins has yielded highly efficacious vaccines. Control of intracellular pathogens has not been achieved, except partly with the BCG vaccine against tuberculosis, and modern efforts are directed towards pathogens against which cellular immune responses are critical. In general, two achievements have been crucial to the success of vaccines: the induction of long-lasting immunological memory in individuals and the stimulation of a herd immunity that enhances control of infectious diseases in populations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10646088     DOI: 10.1016/s0764-4469(00)87191-7

Source DB:  PubMed          Journal:  C R Acad Sci III        ISSN: 0764-4469


  19 in total

Review 1.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

Review 2.  Immunotherapeutic relief from persistent infections and amyloid disorders.

Authors:  Dorian B McGavern
Journal:  Neurology       Date:  2006-01-24       Impact factor: 9.910

3.  In vivo electroporation of minicircle DNA as a novel method of vaccine delivery to enhance HIV-1-specific immune responses.

Authors:  Qingtao Wang; Wei Jiang; Yuhai Chen; Pengyu Liu; Chunjie Sheng; Shuai Chen; Hui Zhang; Changchuan Pan; Shijuan Gao; Wenlin Huang
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

4.  The effects of aflatoxin exposure on Hepatitis B-vaccine induced immunity in Kenyan children.

Authors:  D Githang'a; R N Wangia; M W Mureithi; S O Wandiga; C Mutegi; B Ogutu; A Agweyu; J-S Wang; O Anzala
Journal:  Curr Probl Pediatr Adolesc Health Care       Date:  2019-05-16

5.  Postconditioning hormesis put in perspective: an overview of experimental and clinical studies.

Authors:  F A C Wiegant; H A B Prins; R Van Wijk
Journal:  Dose Response       Date:  2010-08-12       Impact factor: 2.658

6.  A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge.

Authors:  Jackie Pallister; Deborah Middleton; Lin-Fa Wang; Reuben Klein; Jessica Haining; Rachel Robinson; Manabu Yamada; John White; Jean Payne; Yan-Ru Feng; Yee-Peng Chan; Christopher C Broder
Journal:  Vaccine       Date:  2011-07-01       Impact factor: 3.641

7.  OMIP-051 - 28-color flow cytometry panel to characterize B cells and myeloid cells.

Authors:  Thomas Liechti; Mario Roederer
Journal:  Cytometry A       Date:  2018-12-14       Impact factor: 4.355

8.  Vaccine Induction of Lymph Node-Resident Simian Immunodeficiency Virus Env-Specific T Follicular Helper Cells in Rhesus Macaques.

Authors:  Diego A Vargas-Inchaustegui; Andrew Demers; Julia M Shaw; Guobin Kang; David Ball; Iskra Tuero; Thomas Musich; Venkatramanan Mohanram; Thorsten Demberg; Tatiana S Karpova; Qingsheng Li; Marjorie Robert-Guroff
Journal:  J Immunol       Date:  2016-01-15       Impact factor: 5.422

9.  Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.

Authors:  Melissa D Simek; Wasima Rida; Frances H Priddy; Pham Pung; Emily Carrow; Dagna S Laufer; Jennifer K Lehrman; Mark Boaz; Tony Tarragona-Fiol; George Miiro; Josephine Birungi; Anton Pozniak; Dale A McPhee; Olivier Manigart; Etienne Karita; André Inwoley; Walter Jaoko; Jack Dehovitz; Linda-Gail Bekker; Punnee Pitisuttithum; Robert Paris; Laura M Walker; Pascal Poignard; Terri Wrin; Patricia E Fast; Dennis R Burton; Wayne C Koff
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

10.  Vaccination of ferrets with a recombinant G glycoprotein subunit vaccine provides protection against Nipah virus disease for over 12 months.

Authors:  Jackie A Pallister; Reuben Klein; Rachel Arkinstall; Jessica Haining; Fenella Long; John R White; Jean Payne; Yan-Ru Feng; Lin-Fa Wang; Christopher C Broder; Deborah Middleton
Journal:  Virol J       Date:  2013-07-16       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.